Liminatus Pharma forms consortium for pancreatic cancer blood diagnostic with >95% sensitivity

Liminatus Pharma, Inc.

Signed MOU with Samda Biolab and INNOCS AI to develop a blood-based diagnostic kit for early pancreatic cancer detection.
Combined CA19-9 and INNOCS platform achieved >95% sensitivity and >99% specificity in a 1,086-subject cohort.
Liminatus will lead regulatory filings with FDA and KMFDS upon commercialization phase.
Global pancreatic cancer diagnostics market projected at $3B by 2026; blood-based segment >$700M.
Consortium to leverage AI, biomarker platform, and Liminatus's regulatory/commercial infrastructure.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.